Mankind Pharma Reports Strong Q1 FY26 Results with 24.5% Revenue Growth, Announces Interim Dividend
Financial results, especially strong top-line and EBITDA growth coupled with strategic business updates like market share gains, segment outperformance, and BSV integration, directly influence investor perception, stock valuation, and future outlook for the company.
The announcement indicates strong revenue and EBITDA growth, significant outperformance in key therapeutic areas like chronic and anti-infectives, and successful integration of BSV. The management's commentary reflects confidence in future performance. Although PAT declined, the overall operational performance and strategic gains are positive.
* Mankind Pharma Limited announced its financial results for the first quarter ended June 30, 2025 (Q1 FY26), reporting a consolidated revenue from operations of ₹3,570 crore, a year-on-year (YoY) increase of 24.5% from ₹2,868 crore in Q1 FY25. * Earnings Before Interest, Tax, Depreciation, and Amortization (EBITDA) stood at ₹850 crore, up 25.8% YoY from ₹675 crore in Q1 FY25, with an EBITDA margin of 23.8%. * Profit After Tax (PAT) for Q1 FY26 was ₹445 crore, marking a 17.4% decrease from ₹538 crore in Q1 FY25, and diluted EPS was ₹10.6, down 20.1% YoY. * The domestic business revenue grew by 18.9% YoY to ₹3,101 crore, while the exports business revenue saw a significant jump of 81.1% YoY to ₹469 crore, primarily driven by the consolidation of BSV. * Mr. Rajeev Juneja, Vice Chairman & Managing Director, stated that the revenue growth was led by a 1.4x outperformance in the Chronic segment, strong growth in the Consumer segment, and BSV consolidation. * He highlighted encouraging trends with 1.8x volume growth to the Indian Pharma Market (IPM), led by outperformance in Anti-infectives & Respiratory segments, alongside continued strong performance in Cardiology and Anti-Diabetics. * The company's market share increased from 4.8% in March 2025 to 4.9% as of June 2025, maintaining its #1 rank in prescriptions for the last 8 years with a 15.4% share. * Consumer Healthcare segment revenue grew by 15% YoY to ₹237 crore, with strong secondary sales for key brands like Gas-o-fast (+36%), Manforce Condom (+18%), HealthOk (+15%), and Preganews (+12%). * The Board has approved an interim dividend of ₹1 per share, celebrating 30 years of the company's operations.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.